Pharma: Clinic Roundup
Thursday, September 13, 2012
Boehringer Ingelheim GmbH, of Ingelheim, Germany, reported findings at the Asia Pacific Stroke Conference in Tokyo, confirming that, in Asian populations, Pradaxa (dabigatran etexilate) offered considerable benefits for the management of patients with atrial fibrillation.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.